IONS — IONIS PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 874015 ·
Last close
$26.96
Market Cap
$4.49B
52W High
$86.74
52W Low
$26.55
ADV30
4,121,969
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 242,721,000 | 239,399,000 | -130,679,000 | -109,971,000 | 2,912,590,000 | 296,303,000 | 2,518,950,000 |
| Jun 2026 | 267,949,000 | 265,210,000 | -102,297,000 | -114,646,000 | 2,994,501,000 | 350,065,000 | 2,554,764,000 |
| Mar 2026 | 246,091,000 | 243,091,000 | -117,482,000 | -92,528,000 | 3,449,969,000 | 173,381,000 | 2,958,555,000 |
| Dec 2025 | 203,330,000 | 195,373,000 | -214,473,000 | -229,394,000 | 3,523,836,000 | 372,260,000 | 3,034,747,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-544,414,000
Investing CF
$240,688,000
Financing CF
$261,930,000
CapEx
$-78,352,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.32
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,948,340,000
Inventory
$28,578,000
Receivables
$88,340,000
ST Investments
$1,587,604,000
EBIT TTM
$-474,788,000
Pretax Income TTM
$-543,720,000
Interest Exp TTM
$68,932,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$960,092,032
EBITDA
$-548,548,992
Free Cash Flow
$-371,244,512
Enterprise Value
$5,071,705,600
Total Cash
$1,941,186,048
Total Debt
$2,173,091,072
Shares Out
166,545,100
Trailing EPS
$-3.35
Book Value
$2.37
ROE
-108.1%
ROA
-11.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 943,711,000 | -381,717,000 | -381,387,000 | 3,523,836,000 | 3,034,747,000 | 489,089,000 | -268,583,000 |
| Dec 2024 | 705,138,000 | -475,107,000 | -453,897,000 | 3,003,675,000 | 2,415,324,000 | 588,351,000 | -500,947,000 |
| Dec 2023 | 787,647,000 | -353,730,000 | -366,286,000 | 2,990,072,000 | 2,603,386,000 | 386,686,000 | -307,513,000 |
| Dec 2022 | 587,367,000 | -410,191,000 | -269,722,000 | 2,533,876,000 | 1,960,989,000 | 572,887,000 | -274,370,000 |
TTM Snapshot
Revenues TTM
$874,090,000
NetIncome TTM
$-565,174,000
OpCashFlow TTM
—
Assets (Latest)
$2,994,501,000
Forward EPS
$-1.69
Max Pain — expiry 2027-01-15
max pain strike: $37.50 · spot: $27.39 · call oi: 4,679 · put oi: 5,260
Expected Move to 2027-01-15:
±$6.19
(22.60%) —
implied range
$21.20 –
$33.58
· ATM straddle on $27.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | $4.60B | $42.04 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $4.64B | $95.11 | — |
| GIKLY | Grifols SA | $4.69B | $5.55 | — |
| INDV | Supernus, Inc. | $4.28B | $36.28 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
News headlines (Yahoo Finance, 1h cache)
Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
2026-11-17 21:45 · Yahoo
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
2026-11-17 08:03 · Yahoo
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
2026-11-16 17:15 · Yahoo
The Strategy Exited Ionis Pharmaceuticals (IONS) Following Sequential Phase 3 Clinical Setbacks
2026-11-13 14:10 · Yahoo
Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
2026-11-12 15:00 · Yahoo
RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics
2026-11-12 14:06 · Yahoo
Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings
2026-11-11 16:02 · Yahoo
Ionis to present at upcoming investor conferences
2026-11-10 12:05 · Yahoo
Ionis Pharmaceuticals Inc (IONS) (Q3 2026) Earnings Call Highlights: DAWNZERA Momentum and ...
2026-11-10 11:02 · Yahoo
Ionis Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-10 02:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.